Short answer
Foghorn Therapeutics Inc. (FHTX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $3M (down 45.1% year over year) with net income of −$20M.
Q1 2026 key financials · XBRL
- Revenue
- $3M
- −45.1% YoY
- Net income
- −$20M
- −5.5% YoY
- Operating margin
- -660.3%
- EPS (diluted)
- −$0.29
- +3.3% YoY
Source: XBRL data from the Foghorn Therapeutics Inc. (FHTX) Q1 2026 10-Q on SEC EDGAR. USD.
Foghorn Therapeutics Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $3.3M, down from $6.0M YoY, driven by Lilly work timing
- Net loss $19.9M versus $18.8M YoY; operating loss $21.6M versus $22.9M
- R&D expense $18.3M versus $21.6M; Lilly programs $2.3M and FHD-286 $0.8M lower
- Cash, equivalents and marketable securities $183.6M; operating cash outflow $25.3M versus $24.0M YoY
- January 2026 offering net proceeds $49.7M; management expects significant losses and additional funding needs
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- Newly added risk factors: none identified
- Regulatory, legal, and compliance risks unchanged from the 2025 Form 10-K
- Operational, competitive, and market risks unchanged from the 2025 Form 10-K
- Liquidity, debt, currency, and concentration risks unchanged from the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Foghorn Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.